In addition, in patients with MetS, the combination of the two can reduce the plasma levels of plasminogen activator inhibitor-1 and vascular cell adhesion molecule-1 (VCAM-1), both of which are vascular inflammation markers of endothelial dysfunction. This evidence concerns the gene VCAM1 and endothelial dysfunction.